Table 2 Neuroimaging, Laboratory Findings, and Disease Severity in Patients with Tuberculous Meningitis (N = 100)
Variables | Possible (n = 63) | Probable (n = 22) | Definite (n = 15) | Total (n = 100) |
|---|---|---|---|---|
Neuroimaging findings, n (%) | ||||
 Normal | 21/59 (35.6) | 2 (9.1) | 4/14 (28.6) | 27/95 (28.4) |
 Hydrocephalus | 20/59 (33.9) | 11 (50.0) | 7/14 (50.0) | 38/95 (40.0) |
 Meningeal enhancement | 16/59 (27.1) | 13 (59.1) | 5/14 (35.7) | 34/95 (35.8) |
 Cerebral infarction | 11/59 (18.6) | 11 (50.0) | 5/14 (35.7) | 27/95 (28.4) |
 Tuberculoma/abscess | 2/59 (3.4) | 2 (9.1) | 2/14 (14.3) | 6/95 (6.3) |
Laboratory features | ||||
 CSF leucocytes (per µl), median (percentile 25 to percentile 75) | 130.0 (40.0 to 350.0), n = 53 | 66.0 (10.0 to 200.0) | 110.0 (5.0 to 200.0) | 110.0 (20.0 to 295.0), n = 90 |
 CSF pleocytosis, n (%) | 49/53 (92.5) | 18 (81.8) | 12 (80.0) | 79/90 (87.8) |
 CSF polymorphonuclears (%), median (percentile 25 to percentile 75) | 20.0 (5.0 to 50.0), n = 49 | 10.0 (5.0 to 30.0) | 56.5 (10.0 to 85.0), n = 14 | 20.0 (5.0 to 65.0), n = 85 |
 CSF lymphocyte predominance1, n (%) | 36/49 (73.5) | 17 (77.3) | 7/14 (50.0) | 60/85 (70.6) |
 CSF protein (mg/dl), median (percentile 25 to percentile 75) | 138.0 (83.0 to 176.0), n = 54 | 118.0 (96.0 to 167.0), n = 21 | 91.1 (68.0 to 127.0), n = 14 | 122.0 (84.0 to 166.0), n = 89 |
 CSF hyperproteinorrhachia, n (%) | 47/54 (87.0) | 20/21 (95.2) | 14/14 (100.0) | 81/89 (91.0) |
 CSF glucose (mg/dl), median (percentile 25 to percentile 75) | 37.0 (21.0 to 58.0), n = 54 | 27.0 (19.0 to 37.0), n = 21 | 21.5 (15.0 to 43.0), n = 14 | 34.0 (19.0 to 49.0), n = 89 |
 CSF hypoglycorrhachia, n (%) | 30/54 (55.6) | 17/21 (81.0) | 10/14 (71.4) | 57/89 (64.0) |
 Serum sodium (mg/dl), median (percentile 25 to percentile 75) | 137.0 (134.0 to 140.0), n = 56 | 133.0 (131.0 to 136.0) | 131.0 (130.0 to 137.0), n = 14 | 135.0 (131.0 to 140.0), n = 92 |
 ESR (mm/hour), median (percentile 25 to percentile 75) | 24.0 (10.0 to 40.0), n = 53 | 25.0 (10.0 to 43.0), n = 19 | 42.0 (20.0 to 57.0), n = 11 | 25.0 (10.0 to 44.0), n = 83 |
 CRP (mg/L), median (percentile 25 to percentile 75) | 18.8 (6.3 to 52.5), n = 49 | 12.6 (2.2 to 70.5), n = 16 | 32.7 (16.4 to 81.1), n = 10 | 18.8 (5.6 to 53.9), n = 75 |
 Leukocytes (× 103/per µl), median (percentile 25 to percentile 75) | 8.9 (7.3 to 10.6), n = 57 | 8.1 (5.8 to 10.2) | 8.7 (7.3 to 12.5), n = 14 | 8.8 (7.0 to 10.6), n = 93 |
 Hemoglobin (mg/dL), median (percentile 25 to percentile 75) | 13.5 (11.6 to 14.3), n = 57 | 12.3 (9.3 to 13.5), n = 21 | 12.9 (11.3 to 13.7), n = 14 | 13.0 (11.3 to 14.2), n = 92 |
 Platelets (× 103/per µl), median (percentile 25 to percentile 75) | 246.5 (198.0 to 317.0), n = 56 | 249.0 (187.0 to 316.0) | 242.5 (214.0 to 302.0), n = 14 | 245.0 (195.0 to 307.5), n = 92 |
Modified BMRC severity stage, n (%) | ||||
 I | 12 (19.1) | 2 (9.1) | 3 (20.0) | 17 (17.0) |
 II | 37 (58.7) | 18 (81.8) | 8 (53.3) | 63 (63.0) |
 III | 14 (22.2) | 2 (9.1) | 4 (26.7) | 20 (20.0) |
Length of hospital stay (days), median (percentile 25 to percentile 75) | 19.0 (10.0 to 31.0) | 21.0 (13.0 to 27.5), n = 20 | 23.0 (11.0 to 31.0) | 20.0 (11.0 to 30.0), n = 98 |